期刊文献+

围手术期应用度他雄胺对经尿道前列腺等离子切除术出血量的影响

下载PDF
导出
摘要 目的对比围术期是否应用度他雄胺对TURP出血量,评价度他雄胺疗效与安全性。方法以2014年1月到2015年12月,医院收治的择期BPH患者作为研究对象,观察组、对照组各入选50例,前者围术期应用度他雄胺,两组均采用经尿道前列腺等离子切除术治疗。结果观察组退出2例,对照组退出5例;术前,观察组前列腺最大血流速度低于用药前、对照组,观察组术中出血量、术后出血量低于对照组,差异具有统计学意义(P<0.05),两组用药前、术前前列腺体积、手术时间差异无统计学意义(P>0.05);两组均未见不良反应,术后随访均未见再出血。结论围手术期应用度他雄胺可降低经尿道前列腺等离子切除术出血量,可能与其可改变前列腺血流动力学状态有关。
作者 薛金雄
出处 《海峡药学》 2016年第8期164-165,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献3

二级参考文献34

  • 1许云飞.多沙唑嗪、非那雄胺及其联合应用在BPH临床进展中的长期疗效[J].中华男科学杂志,2006,12(12):1149-1150. 被引量:1
  • 2Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002, 60(3) : 434-441.
  • 3Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology, 2004, 63(4) : 709-715.
  • 4Issa MM, Runken MC, Grogg AL, et al. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: Dutasteride versus finasteride. Am J Manag Care, 2007, 13 ( Suppl 1 ) : S10-S16.
  • 5Fenter TC, Davis EA, Shah MB, et al. Dutasteride vs finasteride: Assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or = 65 years. Am J Manag Care, 2008, 14(5 suppl 2) : s154-s159.
  • 6Kaplan SA, McConnell JD, Roehrtom CG, et al. Combination therapy with doxazosin and finastefide for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol, 20(16,175(1) : 217-221.
  • 7Roehrbom CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol, 2010, 57( 1 ) : 123-131.
  • 8Barkin J, Roehrbom CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int, 2009 , 103(7) : 919-926.
  • 9Tsukamoto T, Endo Y, Narita M. Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled, parallel-group, dose response study. Hinyokika Kiyo, 2009, 55(4) : 209-214.
  • 10Schulman C, Pommerville P, Heifner K, et al. Long-term therapy with the dual 5alpha- reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int, 2006, 97(1): 73-79.

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部